Eisai
-8.85%

Pharma / Pharmaceuticals, Healthcare

🚀 Founded 1941 🌎 Japan 🏷️ ESALY JP3160400002 ⭐ 500

ℹ️ Info

🧾 At a Glance 📎 Core Facts 🛍️ Products/Services ⭐ Ratings 🧑‍💼 Executives 💬 My Comments

💡 Analytics

🔔 Insights (2) 🏢 Company Q&A (663) 🛠️ Industry Q&A (164) 🏁 Competitors 📊 Price Low 📈 Price Swings ⚡ SWOT 🏛️ PEST 🌀 Porter's Five Forces ✨ Score Positive ⚠️ Risk Assessment 🧩 Segmentation 🅶 Google Links

💸 Financials

🔄 Cash Flow ⚖️ Balance Sheet 💵 Income Statement 👑 Owner Earnings

📊 Ratios

💰 Margins 📐 Financial Ratios 🌱 Growth 📏 Enterprise Value 📌 Key Metrics 💵 Dividends

🔧 Tools

✅ Due Diligence

📚 Resources

📰 News 🔶 Clusters 🗂️ SEC Filings 🔢 Stock Split History 📢 Press Releases 👤 Insider Trades 📅 Earnings Calendar 🌐 Web 📝 Reports

🔥 Video Insights

[Disclaimer]

Value investing review - Eisai: Is This Japanese Pharma Innovator Being Ignored by the Market?

May 29, 2026

Eisai is a global pharmaceutical company known for its work in neurology, oncology, and innovative drug development. In this video, we examine why the stock price remains weak, review the company’s financial performance, dividend history, growth opportunities, and key risks, and discuss whether the market may be overlooking the long-term potential of its pharmaceutical pipeline. Subscribe for more value investing reviews and company analysis.

Eisai’s Margin Squeeze – What’s Behind the Numbers?

May 16, 2025

Eisai’s financials show a surprising drop in margins, largely tied to its new Alzheimer’s drug, Leqembi. We break down what this means for investors and how to view the company through a value lens.

What is special about us?

Newsletter

Imprint

Disclaimer

×
Disclaimer

InsightfulValue is an independent platform dedicated to value investing research. The information provided on this website is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice.
We are not financial advisors, investment consultants, or licensed consultants. Our analyses, insights, and criteria are based on principles learned from renowned value investors such as Benjamin Graham, Warren Buffett, and Charlie Munger, but they should not be considered personalized investment recommendations.
Investing in financial markets carries risks, and past performance is not indicative of future results. Users of this website should conduct their own due diligence and consult with a qualified professional before making any financial or investment decisions. InsightfulValue assumes no liability for any financial losses or decisions made based on the information provided on this site.
By using this website, you acknowledge and accept that all investments involve risk and that InsightfulValue does not guarantee any financial outcomes.

Legal

Due Diligence

To start evaluating the companies of your choice, sign up or log in.